ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib targets BCR-ABL, PGFRA, and C-Kit and has revolutionized the management of chronic myeloid leukaemia and gastrointestinal stromal tumours, but failed to improve ORR and DCR in patients with R/M ACC [54, 55].